ATE534397T1 - Verwendung von dmbt1 zum einfangen von sulfat- und phosphatgruppen exponierenden agenzien - Google Patents
Verwendung von dmbt1 zum einfangen von sulfat- und phosphatgruppen exponierenden agenzienInfo
- Publication number
- ATE534397T1 ATE534397T1 AT05732131T AT05732131T ATE534397T1 AT E534397 T1 ATE534397 T1 AT E534397T1 AT 05732131 T AT05732131 T AT 05732131T AT 05732131 T AT05732131 T AT 05732131T AT E534397 T1 ATE534397 T1 AT E534397T1
- Authority
- AT
- Austria
- Prior art keywords
- dmbt1
- accessible
- phosphate groups
- sulfate
- capture agents
- Prior art date
Links
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 title abstract 4
- 102100031262 Deleted in malignant brain tumors 1 protein Human genes 0.000 title abstract 3
- 101000844721 Homo sapiens Deleted in malignant brain tumors 1 protein Proteins 0.000 title abstract 3
- 239000003795 chemical substances by application Substances 0.000 title abstract 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical group OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 title 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 abstract 3
- 229910021653 sulphate ion Inorganic materials 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 238000011282 treatment Methods 0.000 abstract 2
- 238000003745 diagnosis Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
- Y10T436/143333—Saccharide [e.g., DNA, etc.]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04004281A EP1568374A1 (de) | 2004-02-25 | 2004-02-25 | Verwendung von DMBT1 zur Bindung von Slfat- und Phosphatgruppen aufweisenden Substanzen |
| PCT/EP2005/001994 WO2005079834A1 (en) | 2004-02-25 | 2005-02-25 | Use of dmbt1 for capturing sulphate and phosphate group exposing agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE534397T1 true ATE534397T1 (de) | 2011-12-15 |
Family
ID=34745899
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05732131T ATE534397T1 (de) | 2004-02-25 | 2005-02-25 | Verwendung von dmbt1 zum einfangen von sulfat- und phosphatgruppen exponierenden agenzien |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US8017124B2 (de) |
| EP (2) | EP1568374A1 (de) |
| AT (1) | ATE534397T1 (de) |
| WO (1) | WO2005079834A1 (de) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015106084A1 (en) * | 2014-01-09 | 2015-07-16 | Uab Research Foundation | Compositions that inhibit and prevent the formation of dental caries and methods of using the same |
| EP4009049A1 (de) | 2020-12-01 | 2022-06-08 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Immobilisierung und magnetische extraktion von pathogenen und pathogenkomponenten |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1015583B1 (de) * | 1997-01-09 | 2005-10-19 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Srcr domäne-enthaltendes protein |
| US6287605B1 (en) * | 1998-04-17 | 2001-09-11 | The Trustees Of The University Of Pennsylvania | Compositions and methods useful in treatment and prevention of HIV-1 infection |
-
2004
- 2004-02-25 EP EP04004281A patent/EP1568374A1/de not_active Withdrawn
-
2005
- 2005-02-25 AT AT05732131T patent/ATE534397T1/de active
- 2005-02-25 US US10/590,657 patent/US8017124B2/en not_active Expired - Fee Related
- 2005-02-25 EP EP05732131A patent/EP1727558B1/de not_active Expired - Lifetime
- 2005-02-25 WO PCT/EP2005/001994 patent/WO2005079834A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005079834A1 (en) | 2005-09-01 |
| US8017124B2 (en) | 2011-09-13 |
| US20080234185A1 (en) | 2008-09-25 |
| EP1727558B1 (de) | 2011-11-23 |
| EP1727558A1 (de) | 2006-12-06 |
| EP1568374A1 (de) | 2005-08-31 |
| WO2005079834A9 (en) | 2005-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Frommann et al. | Auditory P300 in individuals clinically at risk for psychosis | |
| Liu et al. | The relationship between cortical inhibition, antipsychotic treatment, and the symptoms of schizophrenia | |
| EP2046807A4 (de) | Verfahren und reagenzien zur behandlung und diagnose von gefässerkrankungen und altersbedingter makuladegeneration | |
| JP2019524898A5 (de) | ||
| TW200736252A (en) | Novel heteroaryl substituted benzothiazoles | |
| EP1556405A4 (de) | Mutationen in nod2 sind bei patienten mit morbus crohn mit fibrostenosebildung assoziiert | |
| HRP20090221B1 (hr) | Humanizirano protutijelo | |
| EP2001503A4 (de) | Diagnose und behandlung von morbus alzheimer | |
| DE602006014691D1 (de) | DIAGNOSE, BEHANDLUNG UND PRÄVENTION VON GEFÄSSERKRANKUNGEN MITTELS IL-1alpha-AUTOANTIKÖRPERN | |
| BRPI0413556A (pt) | sondas para doenças onde amilóide se acumula, agentes para tingimento de amilóide, drogas para tratamento e profilaxia de doenças com amilóide acumulada e sondas para diagnóstico de emaranhados neurofibrilares e agentes para tingimento de emaranhados neurofibrilares | |
| ATE446102T1 (de) | Behandlung von gewichtsverlust bei patienten mit entzündlichen darmerkrankungen mittels s. boulardii | |
| DE60122673D1 (de) | Methoden zur diagnose und behandlung von herzkrankheiten | |
| EP2005194A4 (de) | Auf hämoglobin basierende verfahren zur prophylaxe, diagnose bzw. behandlung von netzhauterkrankungen | |
| BR0314713A (pt) | Processos e reagentes para o tratamento de doenças e distúrbios associados com nìveis aumentados de citocinas pró-inflamatórias | |
| ATE534397T1 (de) | Verwendung von dmbt1 zum einfangen von sulfat- und phosphatgruppen exponierenden agenzien | |
| DE602007006284D1 (de) | Verfahren zur vorhersage des ansprechens von patienten mit multipler sklerose auf eine interferontherapie und zur diagnose von multipler sklerose | |
| ATE378423T1 (de) | Polymorphismen des menschlichen hpxr gens und ihre anwendung in diagnose und therapie | |
| DE602004027613D1 (de) | Therapeutische, prophylaktische und diagnostische wirkstoffe | |
| EP1363528A4 (de) | Verfahren zur diagnose und behandlung von herzerkrankungen | |
| Semakova et al. | Neuropsychological approach to the organization of assistance to family, which raising child with autism disorders | |
| DE60225845D1 (de) | Zusammensetzungen und verfahren zur diagnose und behandlung von diabetes, insulinresistenz und dyslipidämie | |
| WO2015070084A3 (en) | Nuclear stress response in motor neuron disease and other neurological diseases | |
| Kaur | Effect of advanced techniques in improving upper limb functions in patients with stroke: A comparative study | |
| ATE495750T1 (de) | Sulfatide zur behandlung von autoimmunkrankheiten | |
| Prathap et al. | Occupational allergic contact dermatitis: a clinical study in a tertiary care centre in central kerala |